SPONSOR
Neurocrine Biosciences
Total Trials
3
Recruiting
3
Phases
Phase 3
Neurocrine Biosciences is a clinical research sponsor with 3 registered studies on ClinicalTrials.gov, of which 3 are actively recruiting participants. Research covers conditions including Major Depressive Disorder, Schizophrenia.
The trial portfolio spans Phase 3 studies, reflecting a pipeline that may include early-stage safety evaluations, mid-stage efficacy assessments, and large-scale confirmatory trials. All studies listed here are sourced directly from ClinicalTrials.gov and updated daily.
Frequently Asked Questions — Neurocrine Biosciences
How many clinical trials has Neurocrine Biosciences sponsored?
ClinicalMetric currently tracks 3 clinical trials sponsored by Neurocrine Biosciences, of which 3 are actively recruiting participants. These trials cover conditions including Major Depressive Disorder, Schizophrenia. Trial counts are updated daily from ClinicalTrials.gov and reflect currently registered studies.
What therapeutic areas does Neurocrine Biosciences research focus on?
Neurocrine Biosciences clinical trials span Major Depressive Disorder, Schizophrenia. The research pipeline includes Phase 3 trials, reflecting work from early-stage safety evaluation through large-scale efficacy studies.
How do I participate in a Neurocrine Biosciences clinical trial?
To participate in a Neurocrine Biosciences trial, review the active studies listed on this page, check each trial's specific eligibility criteria on ClinicalTrials.gov, and contact the trial site directly—not the sponsor's headquarters. Trial sites are academic medical centers, hospitals, or specialized research clinics. Your physician can facilitate a referral. ClinicalMetric lists all Neurocrine Biosciences trials with current recruitment status updated daily.
Clinical Trials by Neurocrine Biosciences
NCT06911112 Phase 3
Recruiting
NBI-1065845-MDD3025: Study to Assess the Efficacy and Safety of NBI-1065845 as an Adjunctive Treatment in Participants With Major Depressive Disorder (MDD)
Major Depressive Disorder
NCT07105098 Phase 3
Recruiting
NBI-1117568-SCZ3030: Evaluation of NBI-1117568 in Inpatient Adults With Schizophrenia
Schizophrenia
NCT06966401 Phase 3
Recruiting
Long-Term Study to Assess the Safety and Tolerability of NBI-1065845 as an Adjunctive Treatment in Participants With Major Depressive Disorder (MDD)
Major Depressive Disorder
ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer · Last Reviewed: April 2026 · Data Methodology